MDASI-HN Scores Predict Hypoglossal Neuropathy Risk in Oropharyngeal Cancer

Early Detection of Latent Cranial Neuropathy in Oropharyngeal Cancer Survivorship

Late radiation-associated dysphagia remains a persistent burden for oropharyngeal cancer survivors, with symptoms often peaking within three months but continuing to affect patients for years post-treatment [1]. Recent evidence suggests that hypoglossal neuropathy (damage to the twelfth cranial nerve which controls tongue movement) is a near-universal finding in patients with fibrosis-related swallowing dysfunction, with subclinical nerve damage often detectable via electromyography before overt clinical signs emerge [2]. Despite the significant symptom burden and quality-of-life impact associated with lower cranial neuropathies, there is currently no clinical consensus or standardized guidelines for the long-term assessment of these latent toxicities [3, 4]. Risk factors such as high cumulative radiation doses and continued tobacco use further increase the likelihood of developing chronic speech and voice impairments in this population [5]. A new study now evaluates whether specific patient-reported symptoms can serve as an early warning system for impending nerve failure.

Longitudinal Symptom Tracking in a Large Patient Cohort

The researchers conducted a retrospective analysis of data derived from a prospective cohort of 1297 patients with oropharyngeal cancer who were treated with curative intent. This large-scale investigation took place at the MD Anderson Cancer Center, with data collection spanning from March 2015 to December 2023. The study population was predominantly male, consisting of 1156 (89.1%) male participants and 141 (10.9%) female participants. At the time of enrollment, the cohort had a mean age of 65.9 years (standard deviation of 9.2 years). These demographics reflect the typical patient profile seen in clinical practice for oropharyngeal malignancies, providing a robust dataset for evaluating long-term treatment toxicities. To capture the progression of late-onset side effects, eligible patients completed standardized symptom assessments at baseline and at regular follow-up intervals for a duration of up to 5 years. This longitudinal approach allowed the authors to monitor the evolution of symptoms over time rather than relying on a single cross-sectional snapshot. The primary outcome of interest was the development of hypoglossal (CN XII) neuropathy, a condition that can severely impair tongue mobility and swallowing function. The researchers classified the status of the hypoglossal nerve based on documented clinical signs identified through a structured review of health records. This rigorous data analysis, which was finalized in June 2025, aimed to correlate patient-reported symptom trajectories with the eventual clinical diagnosis of nerve damage.

Quantifying Nerve-Related Symptom Burden

To identify the most reliable indicators of hypoglossal nerve damage, the researchers analyzed the symptom trajectories of six specific items from the MD Anderson Symptom Inventory-Head and Neck (MDASI-HN). These items included chewing/swallowing, choking, speech/voice, mucus, fatigue, and dry mouth. To visualize and interpret these longitudinal data points, the study utilized spaghetti plots (a graphical method that displays individual patient symptom paths over time to reveal both group trends and individual variability). The researchers further refined this analysis using piecewise linear mixed-effects models (a statistical approach that accounts for individual differences while identifying specific time points where the rate of symptom change shifts significantly). By integrating these six clinical indicators, the authors derived a composite symptom-based nerve score known as the MDASI-HN-NERVE score. This metric was specifically developed to quantify the symptom burden associated with hypoglossal (CN XII) neuropathy, offering a structured way to measure the cumulative impact of nerve-related dysfunction on patient function. This composite approach allows clinicians to move beyond isolated symptoms and instead utilize a weighted assessment of the functional deficits most closely linked to cranial nerve XII injury, facilitating more precise monitoring of survivors who may be at risk for late-onset radiation toxicities.

Clinical Thresholds for Risk Stratification

To evaluate the predictive utility of the MDASI-HN-NERVE score, the researchers employed time-dependent Cox models (a statistical method used to estimate the risk of an event occurring over time while accounting for variables that change during the follow-up period) and Kaplan-Meier analyses (a method used to estimate the probability of patients remaining free of a condition over a specific duration). These analyses demonstrated that higher MDASI-HN-NERVE scores were associated with an increased risk of developing hypoglossal (CN XII) neuropathy, yielding a hazard ratio of 1.35 (95% CI, 1.18-1.54). This finding indicates that for every one-unit increase in the composite symptom score, the risk of latent nerve damage rises by 35 percent. For clinicians seeking to implement these findings in a survivorship clinic, the study identified specific score thresholds that effectively stratify patients into high-risk and low-risk categories. An optimal threshold of 3.4 at baseline (prior to treatment) distinguished groups with significantly different rates of CN XII neuropathy-free survival. This risk stratification remained relevant during the early survivorship phase, as an optimal threshold of 3.5 at 3 to 6 months posttreatment also successfully identified patients at a higher risk for latent nerve damage. Beyond the composite score, the researchers found that individual symptom assessments can also serve as early warning signs. Specifically, single-item MDASI speech/voice scores at baseline discriminated the risk of latent CN XII neuropathy. This predictive value persisted into the post-therapy period, where single-item MDASI speech/voice scores at 3 to 6 months posttreatment also effectively identified patients at risk. The study suggests that both the MDASI-HN speech/voice symptoms and the MDASI-HN-NERVE score provide a practical, patient-centered approach for the early detection and monitoring of CN XII neuropathy risk. By utilizing these validated patient-reported outcomes, clinicians can implement a more proactive surveillance strategy in oropharyngeal cancer survivorship care.

References

1. Shah A, Nguyen MT, Nguyen SA, Pelic JC, Davidson K, O’Rourke AK. Longitudinal Patterns of Radiation‐Associated Dysphagia in Patients With Head and Neck Cancer: A Systematic Review. Head & Neck. 2025. doi:10.1002/hed.70107

2. McMillan H, Okoro C, Buoy S, et al. Hypoglossal Neuropathy in the Pathogenesis of Fibrosis‐Related Late‐Radiation Associated Dysphagia: A Correlative Analysis Utilizing Electromyography to Explore the Frequency of Clinical and Subclinical Neuropathy in a Pilot Dysphagia Trial. Head & Neck. 2025. doi:10.1002/hed.70024

3. Sellstrom D, Haighton C, Finch T, O’Hara J, Patterson J. Assessment and management of late radiation‐associated dysphagia after treatment for head and neck cancer: A scoping review and survey of UK speech and language therapists. International Journal of Language & Communication Disorders. 2025. doi:10.1111/1460-6984.13154

4. Aggarwal P, Zaveri J, Goepfert RP, et al. Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngology–Head & Neck Surgery. 2018. doi:10.1001/jamaoto.2018.1791

5. Aggarwal P, Hutcheson KA, Garden AS, et al. Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngology–Head & Neck Surgery. 2021. doi:10.1001/jamaoto.2021.0698